
Feature|Articles|July 7, 2026
Curbing Cognitive Decline in Epilepsy: Introducing Cleveland Clinic’s New HAP-E Pilot Program
Author(s)Marco Meglio
Fact checked by: Nicole Canfora Lupo
Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.
Advertisement
Advertisement
As the global population ages, epilepsy is becoming one of the most common, and most overlooked, neurological conditions of later life: People with epilepsy face nearly triple the risk of developing dementia, dementia patients face a 5- to 10-fold increased risk of developing epilepsy, and older adults now account for roughly a quarter of all first-time seizures.1 Despite the prevalence, few centers are dedicated to the care of patients facing the unique challenges that come with epilepsy in later years of life, including these difficult-to-treat coexisting conditions.
Related to this article

Here's some of what is coming soon to NeurologyLive® this week.

New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Advertisement
Advertisement


